Latest news with #Tegretol-XR
Time of India
3 days ago
- Business
- Time of India
Alembic Pharmaceuticals gets USFDA nod for generic Carbamazepine tablets
Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic version of Carbamazepine extended-release tablets indicated for treatment of seizures, and relieving nerve pain. The approval by the US Food & Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) of Carbamazepine extended-release tablets of strengths 100 mg, 200 mg, and 400 mg, it said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product Tegretol-XR extended-release tablets in the same strengths, of Novartis Pharmaceuticals Corporation, it added. Alembic said Carbamazepine extended-release tablets are indicated for use as an anticonvulsant drug and also for the treatment of the pain associated with true trigeminal neuralgia. Citing IQVIA data for the 12 months ended March 2025, the company said Carbamazepine extended-release tablets of 100 mg, 200 mg, and 400 mg, have an estimated market size of USD 71 million.
News18
3 days ago
- Business
- News18
Alembic Pharmaceuticals gets USFDA nod for generic Carbamazepine tablets
Agency: PTI Last Updated: New Delhi, Jul 28 (PTI) Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic version of Carbamazepine extended-release tablets indicated for treatment of seizures, and relieving nerve pain. The approval by the US Food & Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) of Carbamazepine extended-release tablets of strengths 100 mg, 200 mg, and 400 mg, it said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product Tegretol-XR extended-release tablets in the same strengths, of Novartis Pharmaceuticals Corporation, it added. Alembic said Carbamazepine extended-release tablets are indicated for use as an anticonvulsant drug and also for the treatment of the pain associated with true trigeminal neuralgia. Citing IQVIA data for the 12 months ended March 2025, the company said Carbamazepine extended-release tablets of 100 mg, 200 mg, and 400 mg, have an estimated market size of USD 71 million. PTI RKL ANU ANU Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Upturn
5 days ago
- Business
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
